Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II open-label, single arm study of tislelizumab combined with gemcitabine and cisplatin as a bladder-sparing therapy for urine tumor DNA (utDNA) defined clinical complete response (cCR) MIBC patients

Next Previous
Trial Profile

A Phase II open-label, single arm study of tislelizumab combined with gemcitabine and cisplatin as a bladder-sparing therapy for urine tumor DNA (utDNA) defined clinical complete response (cCR) MIBC patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Epirubicin (Primary) ; Gemcitabine (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms Punch

Most Recent Events

  • 27 Jan 2024 Preliminary results (n=13; By Sep. 2023) assessing the efficacy and safety of intraarterial chemotherapy combined with tislelizumab and bacillus Calmette-Guerin (BCG) as a bladder-preserving treatment for HR NMIBC patients, presented at the 2024 Genitourinary Cancers Symposium.
  • 12 Dec 2023 New trial record
  • 24 Oct 2023 Interim results (n=16; between Jul. 2021 and Sep. 2022) assessing the the efficacy of tislelizumab combined with gemcitabine and cisplatin (GC) as a bladder-sparing therapy for utDNA-defined cCR patients, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top